⚡ Anticoagulation Management for AF Cardioversion
This tool gives the peri-cardioversion anticoagulation strategy for atrial fibrillation by AF duration and hemodynamic stability.
Anticoagulation continues at least 4 weeks after cardioversion regardless of duration or stroke risk, because of thrombus risk during atrial stunning. (original synthesis · not guideline verbatim)
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Use to decide pre-cardioversion anticoagulation (or TEE) and the mandatory post-cardioversion course, separating unstable patients who need immediate cardioversion.
How it works
Unstable → immediate cardioversion, anticoagulate ASAP. < 48 h → anticoagulate at presentation, low-risk may cardiovert directly. ≥ 48 h/unknown → anticoagulate ≥ 3 weeks or TEE-exclude thrombus. All → ≥ 4 weeks after cardioversion.
Key points
- Anticoagulation continues at least 4 weeks after cardioversion regardless of duration or stroke risk, because of thrombus risk during atrial stunning. (original synthesis · not guideline verbatim)
- Long-term anticoagulation is decided by CHA₂DS₂-VASc, not by whether sinus rhythm was achieved.
- A left-atrial-appendage thrombus on TEE defers cardioversion for 4–12 weeks of anticoagulation.
References
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| AF duration | < 48 hours (definite) |
|---|---|
| Hemodynamically unstable | No |
→Pre-cardioversion anticoagulation strategy< 48 h: anticoagulate at presentation, low-risk may cardiovert directly
- Peri-cardioversion：Duration < 48 h: start anticoagulation at presentation (parenteral anticoagulation or NOAC); low thromboembolic risk may be cardioverted directly (high stroke risk should be treated as ≥ 48 h). Continue anticoagulation at least 4 weeks after cardioversion
- After cardioversion：Regardless of sinus-rhythm maintenance or stroke risk, anticoagulate at least 4 weeks after cardioversion (thrombus risk during atrial stunning)
- Long-term anticoagulation：Whether to anticoagulate long-term is decided by CHA₂DS₂-VASc stroke risk (see AF anticoagulation tool), not by whether cardioversion was done or sinus rhythm achieved
| AF duration | ≥ 48 hours or unknown duration |
|---|---|
| Hemodynamically unstable | Yes |
→StrategyImmediate cardioversion (no delay)
- Cardioversion：Hemodynamically unstable (hypotension/myocardial ischemia/acute HF/shock): immediate synchronized cardioversion, not delayed for anticoagulation
- Anticoagulation：Start anticoagulation as soon as possible (UFH/LMWH or NOAC); continue at least 4 weeks after cardioversion
- Long-term：Then decide long-term anticoagulation by CHA₂DS₂-VASc (see AF anticoagulation tool)
Frequently asked questions
- What is Anticoagulation Management for AF Cardioversion?
- This tool gives the peri-cardioversion anticoagulation strategy for atrial fibrillation by AF duration and hemodynamic stability.
- How is Anticoagulation Management for AF Cardioversion calculated? What is the core formula?
- Unstable → immediate cardioversion, anticoagulate ASAP. < 48 h → anticoagulate at presentation, low-risk may cardiovert directly. ≥ 48 h/unknown → anticoagulate ≥ 3 weeks or TEE-exclude thrombus. All → ≥ 4 weeks after cardioversion.
- When is Anticoagulation Management for AF Cardioversion used?
- Use to decide pre-cardioversion anticoagulation (or TEE) and the mandatory post-cardioversion course, separating unstable patients who need immediate cardioversion.
- What are the key clinical points for Anticoagulation Management for AF Cardioversion?
- Anticoagulation continues at least 4 weeks after cardioversion regardless of duration or stroke risk, because of thrombus risk during atrial stunning. (original synthesis · not guideline verbatim) Long-term anticoagulation is decided by CHA₂DS₂-VASc, not by whether sinus rhythm was achieved. A left-atrial-appendage thrombus on TEE defers cardioversion for 4–12 weeks of anticoagulation.
- What are the limits and cautions when using Anticoagulation Management for AF Cardioversion?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Anticoagulation Management for AF Cardioversion calculated in practice? Can you show a worked example?
- Inputs: AF duration < 48 hours (definite), Hemodynamically unstable No → Result: Pre-cardioversion anticoagulation strategy < 48 h: anticoagulate at presentation, low-risk may cardiovert directly（Peri-cardioversion: Duration < 48 h: start anticoagulation at presentation (parenteral anticoagulation or NOAC); low thromboembolic risk may be cardioverted directly (high stroke risk should be treated as ≥ 48 h). Continue anticoagulation at least 4 weeks after cardioversion, After cardioversion: Regardless of sinus-rhythm maintenance or stroke risk, anticoagulate at least 4 weeks after cardioversion (thrombus risk during atrial stunning), Long-term anticoagulation: Whether to anticoagulate long-term is decided by CHA₂DS₂-VASc stroke risk (see AF anticoagulation tool), not by whether cardioversion was done or sinus rhythm achieved） Inputs: AF duration ≥ 48 hours or unknown duration, Hemodynamically unstable Yes → Result: Strategy Immediate cardioversion (no delay)（Cardioversion: Hemodynamically unstable (hypotension/myocardial ischemia/acute HF/shock): immediate synchronized cardioversion, not delayed for anticoagulation, Anticoagulation: Start anticoagulation as soon as possible (UFH/LMWH or NOAC); continue at least 4 weeks after cardioversion, Long-term: Then decide long-term anticoagulation by CHA₂DS₂-VASc (see AF anticoagulation tool)）